PHENYTOIN
Post-Traumatic Seizure Disorder
National Institute of Neurological Disorders and Stroke (NINDS)Small moleculePhase 3Dormant
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 43/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Post-Traumatic Seizure Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Valproic Acid National Institute of Neurological Disorders and Stroke (NINDS) | Phase 3 | B |
PHENYTOIN Cambridge University Hospitals NHS Foundation Trust | Phase 3 | B |
ALLOPREGNAN-3.ALPHA.-OL-20-ONE Michael A. Rogawski, MD, PhD | Phase 2 | B |
Biperiden Hospital Sirio-Libanes | Phase 3 | CC |
Po Brc-003 Dr. Paul Lyons | Phase 2 | NR |
Same molecule, other indications
PHENYTOIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →